Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
Currently, there has been a marked increase in the number of opportunities for relapsed and refractory multiple myeloma treatment due to emergence of new target drugs. These include pomalidomide, a 3 rd generation immunomodulator capable of treating double refractory multiple myeloma (to lenalidomid...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-04-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/330 |